Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). It is still a major public health problem with 250 million chronically HBV-infected patients worldwide with none of the current treatments leading to a cure.
More effective treatments are needed to achieve HBV cure in a large proportion of patients.
We aim to develop a treatment, combining simultaneous stimulation of CD40 and IFN-I pathway, which leads to a strong anti-HBV effect with minimal inflammation.

In this poster we:

• Present the key results that demonstrated the potential of such combination to induce anti-HBV effects in vitro and in vivo
• Introduce the design of our new antibody-based therapeutic that combine the two modalities in one single molecule
• Demonstrate the efficacy of the molecule in HBV infection system in Primary Human Hepatocytes
• Show key results from our preclinical safety assessment in vitro and in vivo in Non-Human Primate

Read our poster to learn more about our research!

_{1 Evotec ID Lyon, 40 avenue Tony Garnier; 69007 Lyon, France}

_{2 Aptuit Verona Srl (an Evotec Company), Via Alessandro Fleming, 4; 37135 Verona, Italy;}

_{3 Sanofi, 13 Quai Jules Guesde, Vitry-sur-Seine, France}